Conference Coverage

Researchers find predictors of worse MS outcomes in post hoc study of three trials


Key clinical point: Certain factors at baseline and over first year of three pooled studies were associated with worse long-term multiple sclerosis outcomes.

Major finding: The number of confirmed relapses in the first year of the FREEDOMS, FREEDOMS II, and TRANSFORMS studies predicted worse subsequent outcomes.

Study details: Pooled data from three phase 3 trials of fingolimod with 2,355 patients.

Disclosures: Dr. Repovic disclosed he is on the speakers bureau for Novartis, the company that sponsored the study.

Source: Repovic P et al. Abstract P210.



SAN DIEGO – Baseline Expanded Disability Status Scale scores and number of relapses during the first year were the most consistent predictors of disability worsening or relapses over the subsequent 3 years in long-term analysis of three phase 3 fingolimod trials.

Those patients identified at higher risk for worse long-term clinical outcomes could benefit from an early review of multiple sclerosis (MS) treatment regimens to help prevent worsening disability, Pavle Repovic, MD, PhD, said in an interview.

Pavle Repovic, a neurologist with the Multiple Sclerosis Center at the Swedish Neuroscience Institute in Seattle Damian McNamara/Frontline Medical News

Dr. Pavle Repovic

“The idea for some time now has been to figure out what will tell whether a patient is responding to a therapy early on or not,” Dr. Repovic said at ACTRIMS Forum 2018, held by the Americas Committee for Treatment and Research in Multiple Sclerosis.

To explore long-term clinical predictors of disability progression and relapse risk, Dr. Repovic and his colleagues analyzed three phase 3 trials assessing fingolimod (Gilenya). They evaluated parameters at baseline and during the first year of the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.


Next Article: